ViiV Healthcare Revenue and Competitors
Estimated Revenue & Valuation
- ViiV Healthcare's estimated annual revenue is currently $434.6M per year.
- ViiV Healthcare's estimated revenue per employee is $201,000
Employee Data
- ViiV Healthcare has 2162 Employees.
- ViiV Healthcare grew their employee count by 8% last year.
ViiV Healthcare's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Head Research and Development | Reveal Email/Phone |
2 | VP, Business Development | Reveal Email/Phone |
3 | Head Translational Research and Cure | Reveal Email/Phone |
4 | Director, HIV Marketing | Reveal Email/Phone |
5 | Finance Manager - Global R&D | Reveal Email/Phone |
6 | Scientific Leader | Reveal Email/Phone |
7 | National Sales Director | Reveal Email/Phone |
8 | Directora regional de ventas | Reveal Email/Phone |
ViiV Healthcare Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $58.9M | 293 | 6% | N/A | N/A |
#2 | $21.1M | 105 | 5% | N/A | N/A |
#3 | $113.4M | 564 | 1% | N/A | N/A |
#4 | $20.9M | 104 | -5% | N/A | N/A |
#5 | $37M | 184 | 9% | N/A | N/A |
#6 | $45.4M | 226 | -24% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $69.7M | 347 | 0% | N/A | N/A |
#9 | $8M | 40 | 3% | N/A | N/A |
#10 | $25.5M | 127 | 28% | N/A | N/A |
What Is ViiV Healthcare?
We are ViiV Healthcare: a global specialist HIV company, 100% focused on researching and delivering new medicines and improving access to care for people living with HIV. Our global headquarters are in Brentford, London UK; with our US headquarters in Research Triangle Park, North Carolina. You can read our Social Media Code of Conduct at: bit.ly/SoMe-VHC
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
2162
Number of Employees
$434.6M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ViiV Healthcare News
Today, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved a new drug application (NDA) for their abacavir,...
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated...
GlaxoSmithKline (GSK) and Pfizer's (PFE) ViiV Healthcare Announces FDA Approval of Cabenuva for HIV. March 29, 2022 1:36 PM. ViiV Healthcare, the global...
Issued: London UK ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Implementation Study in European Locat ...
Press Release SHIONOGI announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598, with potential for ultra long-acting dosing intervals S-365598 aims to build on the success of dolutegravir and cabotegravir with potential to anchor ...